CHAPEL HILL, N.C.--(BUSINESS WIRE)--Nov. 16, 2005--POZEN Inc. (NASDAQ: POZN), a pharmaceutical company focused primarily on products for the treatment of acute and chronic pain, migraine, and other pain-related conditions, today announced the appointment of Everardus Orlemans, Ph.D. as Vice President, Clinical Research. Dr. Orlemans will be responsible for all of the company’s efforts in the conduct of clinical trials to support New Drug Application (NDA) submissions to the Food and Drug Administration (FDA) and other worldwide regulatory bodies. Dr. Marshall Reese, POZEN’s Executive Vice President, Product Development, said, “We are very pleased to have Dr. Orlemans as a part of the POZEN team. Dr. Orlemans has made contributions of major significance in the field of clinical development in Europe, Japan as well as the United States. In particular, his extensive international experience with regulatory submissions will be a great asset to POZEN.” Dr. Orlemans has been responsible for the worldwide submissions/approvals of more than ten NDAs in the United States and another three NDAs in other major markets around the globe. Dr. Orlemans is the co-author of five patents. He began his professional career in clinical development with Organon NV, a renowned pharmaceutical company in The Netherlands before transferring to the United States for Organon Pharmaceuticals USA, Inc. Most recently, Dr. Orlemans was Executive Director of the Clinical Development Unit for Organon in the United States. Dr. Orlemans received a Master of Science degree in Chemistry from Catholic University of Nijmegen located in The Netherlands. He received a Ph.D. degree from the University of Twente, also located in The Netherlands.
